List/Grid Tag Archives: cis-retinoic acid
The Dosing of 13-Cis-Retinoic Acid (Accutane) in Neuroblastoma Therapy
The use of isotretinoin (13-cisRA, Accutane) is one part of a protocol used for the treatment of high-risk neuroblastoma (1). As many neuroblastoma families and patients know, taking this medication can be extremely challenging, especially if a patient is unable to swallow the capsules (2). If this is the case, the 13-cisRA must be extracted from the capsule and either mixed with food to be taken ...
AACR 2011 ~ 102nd meeting
The American Association for Cancer Research (AACR) is the oldest and largest scientific organization in the world focused on every facet of cancer research. AACR was founded in 1907 by 11 physicians and scientists interested in research with the goal to “to further the investigation and spread the knowledge of cancer.” Since then, the AACR has grown to 33,000 members and publishes seven ...
Two years of cis-retinoic acid
A new trial opens: prolonged use of isotretinoin
Aflac ST1001 Prolonged Isotretinoin
Dr Howard Katzenstein at Emory University (Aflac) in Atlanta Georgia is the principal investigator of a single-institution trial to explore the prolonged use of isotretinoin (13-cis retinoic acid, cisRA, and also known as”Accutane”). The phase I trial will accrue 20 children/young adults (under 30 years ...
Latest neuroblastoma related news
Neuroblastoma bits from November 2010
.
Excellent new review article on anti-GD2 antibodies
Just published by Yang and Sondel, this thorough review tracks the evolution of antibodies for neuroblastoma through three generations: murine, chimeric, and humanized, and explains the of mechanisms for tumor kill and results of all prior trials. The summary details all combinations with cytokines, modifications ...
CNCF 2010 ~ Dr Kate Matthay presents update on NANT trials
New Approaches to Neuroblastoma Therapy (NANT) consortium offers trials for relapsed and refractory neuroblastoma
Dr Kate Matthay spoke at the Children’s Neuroblastoma Cancer Foundation CNCF parent conference in Chicago July 10, 2010, detailing the status of several NANT trials. She mentioned that these trials open and close periodically, so contacting the principal investigator is the best way ...
ANR 2010 ~ Late Effects of Neuroblastoma Treatment
C10 (p. 80) “Late effects in neuroblastoma”
Dr Lisa Diller (Boston Children’s/Dana-Farber Cancer Institute) reviewed recent published data on late effects and presented new data in the Neuroblastoma Update Course on June 21st, 2010 at the Advances in Neuroblastoma Research meeting in Stockholm, Sweden. The session was organized by Sue Cohn and Andrew Pearson and chaired by Sue Cohn ...
CNCF 2010 ~ Dr Peter Zage on 3F8 phase II randomized trial
Dr Peter Zage from MD Anderson in Houston TX gave a presentation at the Children’s Neuroblastoma Cancer Foundation (CNCF) conference Saturday July 10, 2010 on the 3F8 randomized trial:
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients (NCT00969722)
This trial is funded by ...
ANR 2010: MIBG avidity, tandem transplant (Korea), and ch14.18 (Germany) updates
MIBG non-avid at diagnosis = better outcome?
POC39 (p. 211) Neuroblastomas with non-avid I-123 MIBG scan and negative urinary catecholamine secretion: A single institute’s experience
PL30 (p. 102) Analysis of MIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma. A Children’s Oncology Group (A3973) report
Dui Yen Soh, Sylvain Baruchel, and Meredith Irwin at Sick Kids in ...
